- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04607850
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
A Phase 1b/2, Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-Vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-Vectored Multigenotype hrHPV Vaccine in Women With Low-grade HPV-related Cervical Lesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study consists of an open label, non-randomised, dose escalation Lead in phase. 9 participants with high-risk HPV, in cohorts of 3 in 3 dose ascending groups, will be vaccinated after SMC safety data reviews.
This is followed by a blinded, randomised Main phase with 96 participants with high-risk HPV, in parallel running dose cohorts (three different doses of ChAdOx1-HPV plus two different doses of MVA-HPV versus placebo plus placebo boost). At least 60 of these participants will take part in the immunogenicity sub-study.
A blinded, randomised expansion phase investigating the effects of up to two different main phase doses against placebo will be further defined prior to commencing this phase of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: General Enquiries
- Phone Number: (+44) 1865818808
- Email: enquiries@vaccitech.co.uk
Study Locations
-
-
-
Antwerp, Belgium, 2650
- UZA
-
Brussels, Belgium, 1090
- UZ Brussel
-
Brussels, Belgium, 1070
- Erasme hospital
-
Gent, Belgium, 9000
- UZ Gent
-
Leuven, Belgium, 3000
- UZ Leuven
-
-
-
-
-
Parnu, Estonia, 80010
- Parnu Hospital Womens and Childrens Clinic
-
Tallinn, Estonia, 10119
- East-Tallinn Central Hospital
-
Tallinn, Estonia, 13419
- North Estonia Medical Centre Foundation Surgery Clinic
-
Tartu, Estonia, 51014
- Tartu University Hospital Womens Clinic
-
-
-
-
-
Aberdeen, United Kingdom, AB25 2ZN
- Aberdeen Royal Infirmary
-
Bristol, United Kingdom, BS2 8EG
- University Hospital Bristol NHS Trust
-
Liverpool, United Kingdom, L8 7SS
- Liverpool Women's NHS Foundation Trust
-
Newcastle Upon Tyne, United Kingdom, NE1 4LP
- Royal Victoria Infirmary
-
Nottingham, United Kingdom, NG5 1PB
- Nottingham University Hospital NHS Trust
-
Oxford, United Kingdom, OX3 9DU
- The University of Oxford, Nuffield Department of Women's & Reproductive Health
-
Preston, United Kingdom, PR2 9HT
- Royal Preston Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females aged ≥25 and ≤55 years of age at screening.
- Persistent hrHPV infection defined as a documented cervical infection with hrHPV type(s) in the 6 to 18 months prior to screening and confirmed at screening (participants in the main and expansion phases only). Participants in the lead-in phase are only required to have the screening result.
- Low- grade cervical lesion (CIN1 or HPV-related change only) confirmed by histology and/or cytology report within the 1 year prior to screening.
Not pregnant or breast feeding and one of the following:
- Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses for at least 12 months and without an alternative medical cause)
Of childbearing potential but agrees to practice highly effective contraception for 4 weeks prior to administration of the first dose of study vaccine and throughout the study until 8 weeks after administration of the second dose. Highly effective methods of contraception include one or more of the following:
- Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant
- Hormonal (oral, intravaginal, transdermal, implantable or injectable). Progestogen-only hormonal contraceptives without inhibition of ovulation are not considered to be highly effective.
- An intrauterine hormone releasing system
- An intrauterine device
- Bilateral tubal occlusion
- Sexual abstinence, only if the participant refrains from heterosexual intercourse during the entire study period and it is the usual lifestyle of the participant
- Willing to abstain from sexual activity for 48 hours prior to all swabbing procedures
Exclusion Criteria:
- Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness, including blood dyscrasias.
Immunosuppression as a result of underlying illness or treatment including:
- Use of high dose corticosteroids ( >10 mg/day prednisone or equivalent) for ≥7 days (inhaled, otic and ophthalmic corticosteroids are permitted)
- Primary immune deficiency disease
- Use of synthetic or biologic disease-modifying antirheumatic drugs
- History of bone marrow or solid organ transplant
- History of any other clinically significant autoimmune or immunosuppressive disease
- Positive diagnostic tests (for human immunodeficiency virus, hepatitis B or hepatitis C) indicating chronic infection.
- Evidence of high grade cervical lesions by colposcopy or by Papanicolaou (Pap) smear test in the 1 year prior to screening.
- Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine, e.g. severe allergy to eggs.
- Receipt of any investigational drug or investigational vaccine within 3 months prior to administration of ChAdOx1-HPV on Day 0, or prior participation in a clinical study of any HPV vaccine.
- Receipt of any adenoviral based vaccine within 3 months prior to administration of ChAdOx1 HPV on Day 0, or plan to receive an adenoviral-based vaccine within 3 months after Day 0.
- Receipt of any live vaccines within the 30 days or inactivated vaccine within the 14 days prior to administration of ChAdOx1-HPV on Day 0 or planned to occur in the 2 months after the Day 0 vaccination.
- Current or history of illicit drug use within the 6 months prior to screening.
- Current or history of severe alcohol abuse within the 6 months prior to screening.
- Any laboratory test which is abnormal and deemed by the Investigator to be clinically significant which will potentially affect the participation in the study.
- Current known infection with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2)
- Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^7 pfu)
|
Trial vaccine
Trial vaccine
|
Experimental: Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
|
Trial vaccine
Trial vaccine
|
Experimental: Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10) vp and MVA-HPV (1 x 10^8 pfu)
|
Trial vaccine
Trial vaccine
|
Experimental: Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
|
Trial vaccine
Trial vaccine
|
Experimental: Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^7 pfu)
|
Trial vaccine
Trial vaccine
|
Experimental: Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^8 pfu)
|
Trial vaccine
Trial vaccine
|
Experimental: Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^8 pfu)
|
Trial vaccine
Trial vaccine
|
Experimental: Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^8 pfu)
|
Trial vaccine
Trial vaccine
|
Placebo Comparator: Group 6 Placebo Saline
Sodium Chloride (0.9%)
|
Saline placebo vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events to measure safety and reactogenicity
Time Frame: 3 months for the lead-in and 12 months for the main phase
|
Measure of adverse events, serious adverse events (SAEs), ≥Grade 3 study vaccine-related adverse events reported.
|
3 months for the lead-in and 12 months for the main phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the dose of ChAdOx1-HPV plus MVA-HPV vaccines for further development
Time Frame: 3 months for lead in phase and 12 months for main phase
|
Measurement of the highest multi-parameter index made of CD4+ magnitude, CD4+ avidity and CD8+ magnitude at peak timepoint
|
3 months for lead in phase and 12 months for main phase
|
Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on the clearance of high risk HPV infection
Time Frame: 12 months for main phase only
|
The percentage of hrHPV infection clearance
|
12 months for main phase only
|
Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on cervical intraepithelial neoplasia (CIN)
Time Frame: 12 months for main phase only
|
The percentage of cervical lesions cleared as determined by colposcopy
|
12 months for main phase only
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines
Time Frame: 3 months for lead in phase and 12 months for main phase
|
This will be assessed by measuring the individual phenotypic subsets of CD4+ and CD8+ T cells induced by vaccination
|
3 months for lead in phase and 12 months for main phase
|
Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines
Time Frame: 3 months for lead in phase and 12 months for main phase
|
This will be assessed by measuring the innate immune response after vaccination compared to baseline
|
3 months for lead in phase and 12 months for main phase
|
Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines
Time Frame: 3 months for lead in phase and 12 months for main phase
|
This will be assessed by measuring the T cell breadth of response to the components of the ChAdOx1-HPV plus MVA-HPV vaccines
|
3 months for lead in phase and 12 months for main phase
|
Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines
Time Frame: 3 months for lead in phase and 12 months for main phase
|
Immune responses after prime and boost vaccinations in cytobrush samples compared to baseline
|
3 months for lead in phase and 12 months for main phase
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HPV001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV Infection
-
National Vaccine and Serum Institute, ChinaSichuan Center for Disease Control and Prevention; Hunan Provincial Center... and other collaboratorsRecruitingHPV-Related Carcinoma | HPV InfectioNChina
-
Lee's Pharmaceutical LimitedUnknownCervical HPV-16 and / or HPV-18 InfectionChina
-
Sinocelltech Ltd.RecruitingHPV Infection Vaccine Safety SCT1000China
-
Ulla Bonde van ZwolUniversity of Southern Denmark; Region of Southern Denmark; MCM Vaccines B.V.Unknown
-
PDS Biotechnology Corp.CompletedHigh-risk HPV Infection and Biopsy-proven CIN1United States
-
Capital Medical UniversityUnknown
-
Kenya Medical Research InstituteMerck Sharp & Dohme LLC; University of WashingtonCompletedHPV Infection | HPV Vaccine | HIV-1-infectionKenya
-
Merck Sharp & Dohme LLCCompletedHPV Infections
-
University of Alabama at BirminghamCompleted
-
Merck Sharp & Dohme LLCSuspended
Clinical Trials on ChAdOx1-HPV
-
François SpertiniUniversity of OxfordCompletedTuberculosis | Mycobacterium Tuberculosis, Protection AgainstSwitzerland
-
Vaccitech (UK) LimitedRecruiting
-
University of OxfordCompleted
-
Vaccitech (UK) LimitedCompleted
-
University of OxfordTerminatedMERS (Middle East Respiratory Syndrome)United Kingdom
-
University of OxfordCompleted
-
CanSino Biologics Inc.Recruiting
-
University of OxfordUniversity of BirminghamCompletedTuberculosisUnited Kingdom
-
Zhejiang Provincial Center for Disease Control...Active, not recruitingMeasles | Rubella | Mumps | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18China